ARS Pharmaceuticals, Inc. SPRY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$197.98M-1,165% | -$171.3M-2,242% | -$80.04M-63.0% | -$48.02M-7.1% | -$15.65M+68.5% | ||
| $1.48M+326% | $1.37M+1,630% | $979K+1,479% | $609K+882% | $348K+444% | ||
| $24.22M+46.6% | $22.1M+52.0% | $20.62M+64.3% | $18.52M+60.1% | $16.52M+60.4% | ||
| —— | —— | $35.78M+4,529% | $22.55M— | $9.3M— | ||
| $14.79M+2.8% | $22.95M+286% | $18.99M+10,279% | $19.18M— | $14.39M— | ||
| —— | —— | $35.61M+27,077% | $28.98M+966% | $19.24M+411% | ||
| -$4.93M-142% | -$656K-111% | $6.88M+704% | $8.45M+1,821% | $11.85M+1,070% | ||
| —— | —— | —— | —— | —— | ||
| -$201K-111% | -$350K-117% | $1.79M— | $1.85M— | $1.88M— | ||
| -$175.07M-755% | -$170.87M-1,361% | -$85.38M-86.2% | -$52.8M-19.6% | -$20.48M+61.7% | ||
| $248K-56.6% | $339K-39.8% | $641K— | $584K— | $571K— | ||
| $222.4M-32.0% | $242.03M-32.0% | $356.61M+57.3% | $270.72M-7.2% | $326.95M+60.2% | ||
| $286M+7.3% | $307M+19.0% | $299M+19.1% | $271.5M+8.6% | $266.5M+21.1% | ||
| —— | —— | —— | —— | —— | ||
| $5.02M+44.1% | $5.68M+88.4% | $5.43M+65.3% | $5.64M+59.7% | $3.48M-40.3% | ||
| $104.03M+42.8% | $104.6M+44.5% | $174.38M+5,204% | $75.02M+2,026% | $72.87M+1,148% | ||
| -$15.54M— | -$9.5M— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| $4.55M— | $5.52M— | $6.06M— | $6.8M— | —— | ||
| -$4.93M-142% | -$656K-111% | $6.88M+704% | $8.45M+1,821% | $11.85M+1,070% | ||
| —— | —— | —— | —— | —— | ||
| $222.4M-32.0% | $242.03M-32.0% | $356.61M+57.3% | $270.72M-7.2% | $326.95M+60.2% | ||
| $286M+7.3% | $307M+19.0% | $299M+19.1% | $271.5M+8.6% | $266.5M+21.1% | ||
| $5.02M+44.1% | $5.68M+88.4% | $5.43M+65.3% | $5.64M+59.7% | $3.48M-40.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$201K-111% | -$350K-117% | $1.79M— | $1.85M— | $1.88M— | ||
| -$175.32M-733% | -$171.21M-1,418% | -$86.02M-86.9% | -$53.38M-20.7% | -$21.06M+60.7% | ||
| -$175.32M-733% | -$171.21M-1,418% | -$86.02M-86.9% | -$53.38M-20.7% | -$21.06M+60.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ARS Pharmaceuticals, Inc. generate?
- ARS Pharmaceuticals, Inc. (SPRY) generated -$175.1M in operating cash flow over the trailing twelve months.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- After $248.0K of capital expenditures, ARS Pharmaceuticals, Inc.'s free cash flow was -$175.3M over the trailing twelve months, down 732.7% year over year.
- Where does ARS Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
